Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. [electronic resource]
Producer: 20100223Description: 489-95 p. digitalISSN:- 1528-0020
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Cyclophosphamide -- administration & dosage
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm -- drug effects
- Female
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell -- blood
- Male
- Middle Aged
- Recurrence
- Rituximab
- Vidarabine -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.